Conference reports

TDF/FTC can be used as PrEP by breastfeeding mothers without risk to the baby

Potential for EFdA as PrEP to prevent HIV transmission in women and their infants

Antibody therapy leads to sustained post-treatment SIV control in macaques

18th International Workshop on Comorbidities, 12-13 September, New York, USA

Fanconi-like lab abnormalities reported with daily PrEP: shows importance of routine kidney monitoring

Bone loss with PrEP in MSM aged 18-24

Neurological side effects with integrase inhibitors cause low rates of discontinuation in clinical practice

Atripla three days a week for two years: pilot switch study reports undetectable viral load with better bone, kidneys and sleep

Raltegravir increases waist circumference more than boosted PIs: greater with use of later ART

Exercise associated with significantly reduced risk of serious health problems and higher CD4 counts in large multicentre US study

21st International AIDS Conference (AIDS 2016), 18-22 July 2016, Durban, South Africa

Four day a week ART: sub-optimal drug levels but few virological failures

Large disparities in costs of antiretrovirals between low- and middle-income countries

High risk of virological failure and loss to follow up postpartum in South Africa

Birth weight and preterm delivery outcomes of vertically vs non-vertically infected HIV positive pregnant women

High death rates among HIV positive women postpartum accessing ARVs

Higher rates of eye complications in HIV positive people on ART

Short reports on selected Durban posters

Global HIV Clinical Forum: Integrase Inhibitors, 16 July 2016, Durban

Raltegravir-based third-line ART in children and adolescents

8th International Workshop on HIV Paediatrics, 15-16 July 2016. Durban, South Africa

Raltegravir in HIV-exposed neonates

Virological response without routine viral load monitoring in children: results from the ARROW trial

Tenofovir-containing ART reduces bone mineral density in breast feeding women: results from IMPAACT P1084s

21st International AIDS Conference (AIDS 2016), 18-22 July 2016, Durban, South Africa

AIDS 2016: online access to conference programme

ZERO: no linked HIV transmissions in PARTNER study after couples had sex 58,000 times without condoms

ZERO HIV transmissions in PARTNER study: most widely reported i-Base article

PrEP studies at AIDS 2016: includes first preclinical data with EFdA

Dual therapy with dolutegravir + 3TC keep viral load undetectable: 48 week results from PADDLE study

Once-daily raltegravir at last available: 48 week results from ONCEMRK study

Dual long-acting cabotegravir plus rilpivirine injections: 48-week results from LATTE-2

Dolutegravir is superior to boosted atazanavir in women in the ARIA study

PROMISE results support WHO recommendations for pregnant and breastfeeding women: more needs to be done to improve ART acceptability and adherence

Sub-Saharan African countries moving quickly to recommend “Treat All”

Efavirenz associated with suicide risk in analysis from START study

CD4:CD8 ratio is more sensitive marker of risk than CD4 counts in analysis from START study

Treatment in primary HIV infection is significantly more likely to normalise CD4:CD8 ratio

Publications launched at AIDS 2016

8th International Workshop on HIV paediatrics, 15-16 July 2016, Durban, South Africa.

No increased resistance with once daily dosing of abacavir and 3TC than twice daily dosing in the ARROW trial

TB 2016, 16-17 July 2016, Durban, South Africa

Universal treatment of multi-drug resistant TB is possible within current budgets with generic production

Shortened nine-month MDR-TB treatment works well in children and adolescents

Levofloxacin: safety and tolerability in HIV positive and negative children treated for MDR-TB

2016 Towards an HIV Cure Symposium, 16-17 July 2016, Durban, South Africa

17th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, 8-10 June 2016, Washington DC, USA

Modelling data might support use of low dose 400 mg efavirenz in pregnancy

Pharmacokinetics of antiretrovirals comparable to that in non-pregnant women from three weeks after delivery

22nd Annual BHIVA Conference, 19-22 April 2016, Manchester

New HBV drugs and non-viral liver disease in HIV positive people

Non-AIDS mortality in England and Wales in HIV positive vs general population

High prevalence of multiple high-risk HPV infections in young HIV positive gay men

Anal cancer and HPV screening in HIV positive people

Increasing demand for community treatment information services

Non alcohol fatty acid liver disease: an emerging problem

HIV positive people on ART have impaired alveolar immunity

International Liver Congress (EASL) 2016, 13-18 April 2016, Barcelona

High cure rates using generic hepatitis C drugs bought online: EASL supports lower cost access for Western countries

Studies of new generic $300 HepC combination of ravidasvir and sofosbuvir for low-income countries

23rd Conference on Retroviruses and Opportunistic Infections (CROI 2016), 22-25 February 2016, Boston

No effect of tenofovir on infant bone mineral content in African study

Use of modelling to predicting paediatric dosing of long acting antiretrovirals

Nevirapine dosing for treatment of neonates

START substudies: increased quality of life from earlier treatment but no impact on vascular function or cardiovascular markers

Post navigation